All News

The circulating RNA hsa_circ_0003416 appears to be downregulated in patients with pulmonary arterial hypertension (PAH), according to new research.

New subsets of patients with systemic lupus erythematosus (SLE) and new therapeutic targets have been discovered in recent years.

Many patients with chronic obstructive pulmonary disease (COPD) do not believe their cases warrant emergency department care.

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

Access to digital health tools to improve patient outcomes and quality of life are lacking among patients with multiple myeloma (MM) who are elderly, at risk of relapse, or live in rural communities, suggesting more tools and guidelines are needed for these populations.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, speaks on the key discussions to be held at the 2022 Community Oncology Conference for in-person attendees.

David Ramsey, MD, PhD, MPH, outlines why patients with diabetes should undergo regular eye examinations.

This new study investigated the relationship between cardiac function and hemodynamics among individuals presenting with heart failure with preserved ejection fraction (HFpEF) and normal levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP).

The FDA is considering a second COVID-19 booster dose of the mRNA COVID-19 vaccines; use of the unproven COVID-19 therapies hydroxychloroquine and ivermectin has been significantly greater in the highest vs lowest Republican vote share counties; infertility treatments associated with vascular and pregnancy-related complications.

Jacob Sands, MD, who leads the small cell lung cancer research program at Dana-Farber Cancer Institute, speaks with The American Journal of Managed Care (AJMC®) about the need for more patients who meet the criteria for lung screening to catch cancer before it reaches an advanced stage.

Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of pemigatinib, the first targeted therapy approved by FDA, only 15% to 25% of patients with CCA were “fit enough to receive second-line chemotherapy.”

The mutation is more common than expected and associated with poor outcomes, according to researchers from St. Jude Children’s Research Hospital.

Biden administration officials request additional funding from Congress to manage the global COVID-19 pandemic; New York delays its COVID-19 booster vaccine mandate for health care workers amid staffing shortages; study finds racism affected treatment decisions and led to care disparities among Black patients.

Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.

Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains advancements in BRCA testing and how genetic testing has become standard of care.

Stephen Schleicher, MD, MBA, chief medical officer of Tennessee Oncology, discusses the practice's plans to continue providing quality oncology care to its patients after the end of the Oncology Care Model (OCM).

Researchers compared drug costs among hospitals, specialty pharmacies, and physician offices.

Survival was 100% among patients who had COVID-19-associated acute respiratory distress syndrome (ARDS), and 83% for those without COVID-19 infection.

Speaking during a webinar presented by the National Alliance of Healthcare Purchaser Coalitions, experts weighed the pros and cons of employer high-deductible health plans (HDHPs) and outlined steps to address challenges raised.

A survey of patients with sleep apnea and those at high risk for it identified key aspects of the care pathway where patients have preferences that may inform future processes.

Myelodysplastic syndrome has a variety of clinical presentations, including bone marrow fibrosis. Previously, the presence of fibrosis has not been considered in disease risk scoring in MDS, but recent research suggests it may be a valuable risk factor.

Statistically significant associations were not seen between the medication and breast, ovarian, bladder, kidney, gastric, or esophageal cancers, and there was a reduced risk of prostate cancer.

According to researchers, their findings warrant close surveillance of weight and BMI/age z-scores for patients with type 2 spinal muscular atrophy (SMA).

This new subanalysis of data from the Rotterdam Study investigated life expectancy among women and men who live a healthy lifestyle and do or do not have heart failure.

Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, discusses interventions and treatments that could prevent lower extremity amputation for people with gout.

Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.

A study published in American Journal of Respiratory and Critical Care Medicine found that sleep disordered breathing in pregnancy led to a higher risk of both metabolic disease and hypertension up to 7 years post partum.

Vitamin D is thought to have neuroprotective effects and it is usually lacking in patients with Parkinson disease (PD).

This new study aimed to identify metabolic differences in endothelial cells in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (PH) to aid in the development of novel therapeutic approaches.

Colette Romero, an advocate for eosinophilic esophagitis (EoE) awareness, discusses the steps her family went through to find a therapy plan that worked for her son.